Global Daptomycin Market Size, Share & Trends Report by Indication (Skin Structure Infections, Bacteremia), by Age Group (Pediatric and Adults), and by End-User (Pharmaceutical, Clinics and wellness Centers) Forecast (2022-028)

The global daptomycin market is anticipated to grow at a significant CAGR during the forecast period (2022-2028).Daptomycin is a cyclic lipopeptide antibiotic derived from the organism streptomyces roseosporus. Daptomycin is used to treat certain blood infections such as sepsis or skin infections caused by bacteria in adults and children 1 year of age and older. The daptomycin injections are anticipated to play a significant role in the prevention of blood infections, which in turn will drive the growth of the global daptomycin market during the forecast period.

 

According to the data published by World Health Organization (WHO) in September 2020, Sepsis affects vulnerable populations such as newborns, pregnant women, and people living in low-resource settings. Approximately 85.0% of sepsis cases occur in these settings. Approximately, 49 million cases occur annually among children, resulting in 2.9 million deaths, which could be prevented by early diagnosis and access to safe and affordable medicines and vaccines.

 

According to the data published by National Center for Biotechnology Information (NCBI) in 2020, the prevalence of skin disease is influenced by the overall ecosystem of the region including socio-culture, genetics, and nutrition. It varies from 4.2% to 11.0% in the general population. However, as per the same source, the prevalence of skin disease accounted for 30.0%-40.0% in the pediatric population. Also, Central India which is composed of Madhya Pradesh and Chhattisgarh registered a prevalence of 60.0% of skin diseases. Therefore, the rise in the prevalence of skin disease across the globe is anticipated to propel the growth of the daptomycin market globally.

 

Looking towards the demand for daptomycin, key market players are adopting various strategies including mergers & acquisitions, geographical expansion, partnerships, strategic collaborations, and new product launches to stay competitive in the market. For instance, in March 2021, Mellinta Therapeutics Llc has received US FDA approval for Kimyrsa for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicilin resistant staphylococcus aureus (MRSA).

 

Moreover, in July 2020, Sandoz announced the market introduction of Daptomycin for injection 500 mg and an AP-rated generic version of Cubicin. These injections are used to treat complicated skin and skin structure infections (cSSSI) in adults, caused by Gram-positive bacteria and certain bloodstream infections, including right-sided infective endocarditis.

 

In addition, in September 2019, Cipla has launched Daptomycin for  Injection, 500m/g single dose, AP-rated generic equivalent of cubicin for injection in the US market. The injection is used to treat complicated skincare diseases in the US market. Thus, such product launches coupled with US FDA approvals are anticipated to drive the global daptomycin market during the forecast period.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Age Group
  • By Indication
  • By End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape– Merck & Co., Teva Pharmeceutical Industries Ltd., and Sandoz International GmbH among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

 

Global Daptomycin Market Report by Segment

 

By Indication

• Skin structure Infections
• Bacteremia

By Age Group

• Pediatric
• Adults

By End-User

• Pharmaceutical
• Wellness Centres
• Clinics

 

Global Daptomycin Market Report by Region

 

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa